prepared gold nanorod complex of heptad repeat 1 (HR1) peptide inhibitors for Middle East respiratory syndrome coronavirus (MERS‐CoV) disease.[215] This gold nanorod complex was biocompatible and metabolically stable and displayed 10‐fold higher inhibition of membrane fusion between host cells and MERS‐CoV via HR1/HR2‐mechanism as compared to that of the free inhibitor treatment. Here, CDCA7L is linked to glycogen storage disease VI.